CD274 and neoplasm: These findings suggest that M1-MVs can reprogram immunosuppressive M2 tumor-associated macrophages toward a pro-inflammatory M1 phenotype, potentially enhancing anti-tumor immune responses and improving the efficacy of PD-1/PD-L1 checkpoint inhibitors.